Sensitivity and resistance to DNA damage response inhibitors in acute myeloid leukemia with spliceosome mutations
Description of the granted funding
Acute myeloid leukemia (AML) is an aggressive blood cancer treated with combination chemotherapy. The development of therapy for AML has been slow, and the standard chemotherapy has remained unchanged for decades. Spliceosome mutations are recurrent drivers of AML pathogenesis. Recent research shows that spliceosome mutations induce a DNA damage response vulnerability that can be targeted therapeutically. This study identifies new drug sensitivities in spliceosome mutated AML.
Show moreStarting year
2020
End year
2024
Granted funding
Funder
Research Council of Finland
Funding instrument
Postdoctoral Researcher
Other information
Funding decision number
334273
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
cancer